Harrow to acquire Melt Pharmaceuticals, expanding non-opioid sedation

Harrow, Inc. (NASDAQ:HROW) is acquiring clinical-stage Melt Pharmaceuticals, Inc., securing MELT-300, a non-opioid, non-intravenous procedural sedation therapy that demonstrated superiority in a pivotal Phase 3 study and is targeted for FDA submission in 2027 and a 2028 commercial launch. This strategic acquisition, supported by Harrow's strong financial health, recent $250 million senior unsecured notes offering, and a 67% stock return over six months, aims to expand its market presence beyond ophthalmology into broader procedural sedation, a move underscored by analysts' "strong buy" consensus and a B.Riley price target increase to $70, citing Harrow's goal of achieving a $1 billion-plus revenue run-rate by 2028.

Analysis

Harrow, Inc. (HROW) is executing a strategic acquisition of its former subsidiary, Melt Pharmaceuticals, to fully control the promising late-stage asset MELT-300. This non-opioid, sublingual sedation therapy has demonstrated statistical superiority in its pivotal Phase 3 study, which was conducted under a Special Protocol Assessment with the FDA, thereby reducing regulatory risk. The acquisition directly supports Harrow's growth strategy by providing a clear pathway to expand from its core ophthalmology market into the broader procedural sedation market, targeting a 2027 New Drug Application and a 2028 commercial launch. This move is underpinned by a strong financial position, evidenced by 48% trailing-twelve-month revenue growth, a recent $250 million senior notes offering, and analyst forecasts for profitability this year. The company's plan to transition its existing MKO Melt customer base to the FDA-approved MELT-300 offers a built-in commercial runway, supporting analyst confidence, which includes a strong buy consensus and B.Riley's $70 price target based on a projected $1 billion-plus revenue run-rate by 2028.

Key Decisions for Investors

• Given the acquisition of a de-risked, late-stage asset with positive Phase 3 data, investors may consider the stock's recent 67% six-month return as validation of its growth strategy and view current levels as a potential entry point, aligning with the strong analyst buy consensus.
• Investors should closely monitor key catalysts for further valuation upside, including management's strategic updates at the upcoming Investor & Analyst Day, the timely submission of the MELT-300 New Drug Application in 2027, and progress toward the $1 billion revenue goal.
• While the outlook is positive, it is prudent to assess the execution risk involved in converting the existing customer base to MELT-300 post-launch and to monitor the impact of the new 8.625% senior notes on the company's debt service coverage and overall financial health.